Cellyan Biotechnology (HKPD) Cash & Equivalents (2024 - 2025)
Cellyan Biotechnology's (HKPD) quarterly Cash & Equivalents came in at $749121.0 in Q3 2025, up 19.43% year-on-year from $627257.0 in Q3 2024, and little changed on a QoQ basis from $748721.0 in Q1 2025.
Cellyan Biotechnology (HKPD) Cash & Equivalents (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Cash & Equivalents data on file, last reported at $749121.0 in Q3 2025.
- On a quarterly basis, Cash & Equivalents rose 19.43% year-over-year to $749121.0 in Q3 2025; TTM through Sep 2025 was $749121.0, a 19.43% increase from a year earlier, with the FY2025 full-year figure at $748721.0, up 19.36% from the prior year.
- Cash & Equivalents for Q3 2025 stood at $749121.0, roughly flat from $748721.0 in the prior quarter.
- Over the last five years, Cash & Equivalents for HKPD reached as high as $749121.0 in Q3 2025 and fell as low as $627257.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 105.15 Bn | 101.18 Bn | 4.04 Bn | 3.98 Bn |
| 2 | Cencora | 60.58 Bn | 58.40 Bn | 3.59 Bn | 2.18 Bn |
| 3 | Cardinal Health | 53.81 Bn | 49.87 Bn | 2.50 Bn | 3.94 Bn |
| 4 | Henry Schein | 9.71 Bn | 9.57 Bn | 1.07 Bn | 138.00 Mn |
| 5 | Akso Health | 3.28 Bn | 3.28 Bn | - | 200,000.00 |
| 6 | 111 | 651.73 Mn | 572.63 Mn | 23.58 Mn | 72.04 Mn |
| 7 | Accendra Health | 248.02 Mn | -88.86 Mn | 278.03 Mn | 336.88 Mn |
| 8 | Edap Tms | 230.14 Mn | 215.14 Mn | 8.15 Mn | 15.00 Mn |
| 9 | VitaNova Life Sciences | 11.51 Mn | 11.01 Mn | 316,343.00 | 493,283.00 |
| 10 | Cellyan Biotechnology | 4.19 Mn | 3.44 Mn | - | 749,121.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 749,121.00 |
| Mar 31, 2025 | 748,721.00 |
| Sep 30, 2024 | 627,257.00 |
| Mar 31, 2024 | 627,257.00 |